A fertility treatment company called OvaScience, claims it can “increase IVF success rates by improving egg health, increasing egg reserve and developing the next generation of IVF“. They say their AUGMENTSM treatment method aims to improve the health of an egg’s mitochondria, which are the tiny powerhouses that give cells the energy to divide and grow.
But experts advise caution over those claims. Although some early evidence suggests aging mitochondria could reduce a woman’s fertility, expert say, there are no studies that prove the new method will work. In addition, the company isn’t forthcoming with details of its process…
Read Can You Really Freshen Up Women’s ‘Aging’ Eggs?livescience, March 20, 2015.
OUVERTURE DE la JOURNEE 9h00 Discours d’accueil : Famili ; Association MAIA ; Imany Marraine de cette journée ; Dr Thierry Harvey (Diaconesses)
PREVENIR ET COMBATTRE L’INFERTILITE 10h possibilités & moyens, facteurs environnementaux facteurs psy : le poids des histoires perso dans l’infertilité, grossesse tardive et cryo …
Dr Christophe Siffer (Jean-Verdier) ; Dre Silvia Alvarez (Eylau-La Muette) ; Dre DAVY (La Muette) ; Dre Laurence Levy Dutel (Tenon) Dre Joelle Desjardin (psy) ; Dr Bernard Jegou (environnement et fertilité) Associations Fertilité Europe et Lydia Sophrologue de MAIA
ENDOMETRIOSE, DISTILBENE, SYNDROME MRKH ET CANCERS 11h30
Imany représentera EndoMind Marraine de cette journée Pr Grynberg (Jean-Verdier Bondy) ; Pf Paniel /MRKH (Creteil) Pf Tournaire /DES (SVP) ; Réseau DES Assoc LiliH contre l’endométriose ; MRKH Amélie VICTOR
Discussion avec les associations et pause déjeuner 12h30 à 14h15
PARENTALITE ET GENETIQUE 14h30
Chromosomes, épigénétique dans l’infertilité et la parentalité Dons d’ovocytes : est-ce que mon enfant me ressemblera ? être parent sans génétique, qu’est-ce qui fait que l’on est parent ? Dr HARVEY Thierry (Diaconesses) ; Dr Marie-Charlotte DUMARGNE (Institut PASTEUR) Dr Laurence FRANCOIS (psychiatre assoc MAIA) ; ADEDD Jérôme COURDURIES Maître de conférences Anthropologue ; Pf Lansac (Collège national des gynécologues) ; Dr Rassoulzadegan, (Nice)
TRAITEMENT DE L’INFERTILITE 16h30
Où la FRANCE en est elle ? Accès au remboursement ? au traitement ? au diagnostic ? Qualité des protocoles ? des centres FIV, de la recherche ? Se tourner vers l’étranger ? Pf RAVEL (CECOS RENNES) ; Pf Olivennes (La Muette) ; Dre GALLO (IVI Barcelonne) Pf Jean-Marc Ayoubi (Foch) ; Dr Philippe Durand (spermato in vitro) Irène Thery Sociologue (Directrice d’études à l’EHESS) ; Association MAIA Isabelle Chandler Dr Debbie Montjean (spécialiste ICSI)
La 2ème journée nationale de l’infertilité 2015, événement ouvert à tous, organisée par l’association Maia et le magazine Famili. aura lieu de 9 h à 18 h le 25 septembre 2015 à l’université de médecine Paris-Descartes ,15, rue de l ‘école de médecine PARIS 6 éme (Métro Odéon ou Cluny-Sorbonne). Voir la 1ère journée 2014.
Children born from IVF or in vitro fertilization increased risk of developing cancer . Research results of scientists from Denmark indicates that babies born from fertility treatment outcomes 33 percent higher chance of suffering from cancer since she was a childhood .
Types of cancer are also not arbitrary . According to research , these babies are 65 percent greater risk of suffering from blood cancer ( leukemia ) , and 88 percent greater brain cancer and central nervous system .
Objective To clarify the association between fertility treatment and the risk for cancer in children.
Patient(s) Twenty-five cohort and case-control studies involving children born after fertility treatment as the exposure of interest and cancer as the outcome.
Main Outcome Measure(s) Medline was searched through September 2012 to identify relevant studies. The study-specific estimates for each cancer outcome were combined into a pooled relative risk (RR) with 95% confidence interval (CI) by a meta-analytic approach.
Result(s) We found that children born after fertility treatment were at increased risk for all cancers (RR = 1.33; 95% CI, 1.08–1.63) and for hematological cancers (RR = 1.59; 95% CI, 1.32–1.91), central nervous system/neural cancers (RR = 1.88; 95% CI, 1.02–3.46), and other solid cancers (RR = 2.19; 95% CI, 1.26–3.80). For specific cancer types, we found increased risks for leukemias (RR = 1.65; 95% CI, 1.35–2.01), neuroblastomas (RR = 4.04; 95% CI, 1.24–13.18), and retinoblastomas (RR = 1.62; 95% CI, 1.12–2.35) associated with fertility treatment.
Conclusion(s) The results of the largest meta-analysis on this topic to date indicate an association between fertility treatment and cancer in offspring. However, our results do not rule out that factors related to underlying subfertility, rather than the procedure itself, are the most important predisposing factors for childhood cancer.
Intended as a message of hope rather than a ‘how to’ book, A Dream Come True is the inspiring story of one woman’s path to motherhood via fertility treatment using a donated embryo.
Kitty Alexander describes the torment of not being able to have a child naturally, the other routes to parenthood she tried and considered and the process of her fertility treatment. She then moves on to describe the joy of pregnancy and birth, and to the way she has told her son the truth about his origins.
A Dream Come True includes the story she wrote for her son in which she explains everything to him. A deeply positive book, the author hopes it will inspire women who, like her, know what it is like to be faced with an unstoppable tide of longing to become a parent.
Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment
A 30-year-old woman in Japan who stopped having regular periods and was thought to be infertile was able to become pregnant and give birth thanks to a new experimental fertility treatment…
Human ovaries hold follicles containing oocytes. When follicles mature, they release eggs for fertilization. Patients with primary ovarian insufficiency develop menopausal symptoms at less than 40 y of age. They have few remaining follicles and their only chance for bearing a baby is through egg donation. The researchers demonstrated that Hippo and Akt signaling pathways regulate follicle growth. Using an in vitro activation approach, they first removed ovaries from infertile patients, followed by fragmentation to disrupt Hippo signaling and drug treatment to stimulate Akt signaling. After grafting ovarian tissues back to patients, the researchers found rapid follicle growth in some patients and successfully retrieved mature eggs. After in vitro fertilization, embryo transfer and 37 weeks of pregnancy, a healthy baby boy was born.
Primary ovarian insufficiency (POI) and polycystic ovarian syndrome are ovarian diseases causing infertility. Although there is no effective treatment for POI, therapies for polycystic ovarian syndrome include ovarian wedge resection or laser drilling to induce follicle growth. Underlying mechanisms for these disruptive procedures are unclear. Here, we explored the role of the conserved Hippo signaling pathway that serves to maintain optimal size across organs and species. We found that fragmentation of murine ovaries promoted actin polymerization and disrupted ovarian Hippo signaling, leading to increased expression of downstream growth factors, promotion of follicle growth, and the generation of mature oocytes. In addition to elucidating mechanisms underlying follicle growth elicited by ovarian damage, we further demonstrated additive follicle growth when ovarian fragmentation was combined with Akt stimulator treatments. We then extended results to treatment of infertility in POI patients via disruption of Hippo signaling by fragmenting ovaries followed by Akt stimulator treatment and autografting. We successfully promoted follicle growth, retrieved mature oocytes, and performed in vitro fertilization. Following embryo transfer, a healthy baby was delivered. The ovarian fragmentation–in vitro activation approach is not only valuable for treating infertility of POI patients but could also be useful for middle-aged infertile women, cancer patients undergoing sterilizing treatments, and other conditions of diminished ovarian reserve.